Arrowhead Research | ARWR - 税前利润



金融业
股票价格
USD
资产
USD 2.27B
现金及等价物
USD 201.64M
流动资产
USD 1.84B
流动负债
USD 295.22M
债务
USD 312.77M
EBIT
USD -141.26M
EBITDA
USD 57.17M
员工
711
EPS每股收益
USD -0.93
股本和储备
USD 613.98M
销售毛利
USD 264.03M
债务利息支出
USD 22.51M
利息收入
USD 9.69M
贷款资金
USD 1.23B
市值
USD 8.78B
净收入
USD -132.73M
营业费用
USD 215M
营业利润
USD -141.26M
普通股股本
USD 137.39M
PE价格收益
41.67
税前利润
USD 28.27M
销售收入
USD 73.74M
销售和管理费用
USD 41.74M
股票
USD -173.09M
贸易债权人
USD 30.75M
应收帐款人
USD 15.69M


税前利润 更改 日
Agios Pharmaceuticals USD -99.11M 9.94M 2026-03
Alnylam Pharmaceuticals USD 221.65M 60.52M 2026-03
Anika Therapeutics USD 764K 3M 2025-12
Arrowhead Research USD 28.27M 7.85M 2025-12
Heron Therapeutics USD -2.95M 14.54M 2025-12
Incyte USD 343.6M 46.34M 2026-03
Ionis Pharmaceuticals USD -93M 135M 2026-03
Ligand Pharmaceuticals USD 56.78M 84.36M 2025-12
Merck USD 3.42B 3.32B 2025-12
Moderna USD -799M 612M 2025-12
Nektar Therapeutics USD -34.7M 2.35M 2025-12
Novartis USD 3.84B 802M 2026-03
Sarepta Therapeutics USD 343.17M 750.85M 2026-03
TG Therapeutics USD 20.36M 24.73M 2026-03
Ultragenyx Pharmaceutical USD -184M 56M 2026-03
Vertex Pharmaceuticals USD 1.25B 78.1M 2026-03
Xencor USD -128.64M 124.37M 2026-03